ELOA抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P05398(ELOA Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

**Background of ELOA Antibody**

The ELOA (Elongin A) antibody targets the Elongin A protein, a critical component of the RNA polymerase II transcription elongation complex. Elongin A, encoded by the *ELOA* gene, functions as a transcriptional regulator by enhancing the elongation efficiency of RNA polymerase II, particularly under stress conditions. It forms a heterotrimeric complex with Elongin B and Elongin C, which stabilizes the interaction and facilitates recruitment to sites of DNA damage or paused transcription machinery.

ELOA is also a subunit of the multi-protein CRL (Cullin-RING ubiquitin ligase) complexes, contributing to ubiquitination processes that regulate protein degradation. Dysregulation of Elongin A has been implicated in cancer, neurodegenerative diseases, and autoimmune disorders, making it a focus for therapeutic and diagnostic research. For instance, its interaction with the von Hippel-Lindau (VHL) tumor suppressor protein links it to hypoxia response pathways and renal cell carcinoma pathogenesis.

Antibodies against ELOA are essential tools in studying transcriptional regulation, DNA repair mechanisms, and disease biomarkers. They are widely used in techniques like immunoprecipitation, Western blotting, and immunohistochemistry to explore Elongin A's expression, localization, and interactions in cellular models or clinical samples. Research on ELOA antibodies continues to advance understanding of gene expression control and potential therapeutic targets in oncology and beyond.